Web Exclusives

An online educational tool about PARP inhibitors improved clinicians’ confidence in their ability to use them correctly in women with newly diagnosed advanced ovarian cancer. Read Article ›

Establishing protocols for side-effect reporting and management beforehand can maximize adherence to PARP inhibitor maintenance therapy. Read Article ›

Although the combination of bevacizumab and olaparib showed superior progression-free survival compared with bevacizumab plus placebo as upfront maintenance therapy in women with advanced ovarian cancer, the lack of an olaparib monotherapy comparator limits meaningful interpretation. Read Article ›

The rate of overall survival was similar between nivolumab and either gemcitabine or pegylated liposomal doxorubicin in the open-label, randomized phase 3 NINJA clinical trial of patients with platinum-resistant ovarian cancer, but the overall duration of response was longer in the nivolumab arm. Read Article ›

In the FORWARD II clinical trial, mirvetuximab soravtansine combined with carboplatin and bevacizumab induced an overall response rate of 83% in patients with recurrent platinum-sensitive ovarian cancer. Read Article ›

Copay maximizer programs are replacing copay accumulator programs, and the trend toward increasing cost burden for patients continues. Read Article ›

The combination of dabrafenib and trametinib performs as well in the real world as in clinical trials in patients with BRAF V⁶⁰⁰-mutated advanced melanoma and brain metastases, but the medical need for patients with brain metastases remains high. Read Article ›

The combination of ipilimumab and anti–PD-1 therapy showed efficacy comparable to clinical trial populations in patients with preexisting autoimmune disease and advanced melanoma. Read Article ›

A review of posts to health-related social media over a 5-year period reveals that symptoms and their impact are the most frequently discussed topics by patients with melanoma and their caregivers. Read Article ›

In a landmark single-institution analysis of patients with advanced melanoma, those who stopped their immunotherapy within 7 months of achieving a complete response had comparable disease-free survival to those who were treated for longer than 7 months. Read Article ›

Real-world analysis suggests that ipilimumab/nivolumab should be considered over a single-agent PD-1 inhibitor for metastatic melanoma, regardless of BRAF status. Read Article ›

Lorlatinib (Lorbrena) significantly improved progression-free survival (PFS) and intracranial response rates compared with the former standard of care, crizotinib (Xalkori), as first-line treatment for patients with advanced ALK-positive non–small-cell lung cancer (NSCLC), as reported in a planned interim analysis of the CROWN trial. Read Article ›